1
|
Prado P, Medel V, Gonzalez-Gomez R, Sainz-Ballesteros A, Vidal V, Santamaría-García H, Moguilner S, Mejia J, Slachevsky A, Behrens MI, Aguillon D, Lopera F, Parra MA, Matallana D, Maito MA, Garcia AM, Custodio N, Funes AÁ, Piña-Escudero S, Birba A, Fittipaldi S, Legaz A, Ibañez A. The BrainLat project, a multimodal neuroimaging dataset of neurodegeneration from underrepresented backgrounds. Sci Data 2023; 10:889. [PMID: 38071313 PMCID: PMC10710425 DOI: 10.1038/s41597-023-02806-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2023] [Accepted: 11/30/2023] [Indexed: 12/18/2023] Open
Abstract
The Latin American Brain Health Institute (BrainLat) has released a unique multimodal neuroimaging dataset of 780 participants from Latin American. The dataset includes 530 patients with neurodegenerative diseases such as Alzheimer's disease (AD), behavioral variant frontotemporal dementia (bvFTD), multiple sclerosis (MS), Parkinson's disease (PD), and 250 healthy controls (HCs). This dataset (62.7 ± 9.5 years, age range 21-89 years) was collected through a multicentric effort across five Latin American countries to address the need for affordable, scalable, and available biomarkers in regions with larger inequities. The BrainLat is the first regional collection of clinical and cognitive assessments, anatomical magnetic resonance imaging (MRI), resting-state functional MRI (fMRI), diffusion-weighted MRI (DWI), and high density resting-state electroencephalography (EEG) in dementia patients. In addition, it includes demographic information about harmonized recruitment and assessment protocols. The dataset is publicly available to encourage further research and development of tools and health applications for neurodegeneration based on multimodal neuroimaging, promoting the assessment of regional variability and inclusion of underrepresented participants in research.
Collapse
Affiliation(s)
- Pavel Prado
- Latin American Brain Health Institute (BrainLat), Universidad Adolfo Ibáñez, Santiago, Chile
- Escuela de Fonoaudiología, Facultad de Odontología y Ciencias de la Rehabilitación, Universidad San Sebastián, Santiago, Chile
| | - Vicente Medel
- Latin American Brain Health Institute (BrainLat), Universidad Adolfo Ibáñez, Santiago, Chile
| | - Raul Gonzalez-Gomez
- Latin American Brain Health Institute (BrainLat), Universidad Adolfo Ibáñez, Santiago, Chile
| | | | - Victor Vidal
- Latin American Brain Health Institute (BrainLat), Universidad Adolfo Ibáñez, Santiago, Chile
| | - Hernando Santamaría-García
- PhD Neuroscience Program, Physiology and Psychiatry Departments, Pontificia Universidad Javeriana, Bogotá, Colombia
- Memory and Cognition Center Intellectus, Hospital Universitario San Ignacio, Bogotá, Colombia
- Global Brain Health Institute, University of California San Francisco, San Francisco, USA
- Global Brain Health Institute, Trinity College Dublin, Dublin, Ireland
| | - Sebastian Moguilner
- Latin American Brain Health Institute (BrainLat), Universidad Adolfo Ibáñez, Santiago, Chile
- Cognitive Neuroscience Center (CNC), Universidad de San Andrés & CONICET, Buenos Aires, Argentina
- Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
| | - Jhony Mejia
- Latin American Brain Health Institute (BrainLat), Universidad Adolfo Ibáñez, Santiago, Chile
- Departamento de Ingeniería Biomédica, Universidad de Los Andes, Bogotá, Colombia
- Memory and Aging Clinic, University of California San Francisco, San Francisco, USA
| | - Andrea Slachevsky
- Neuropsychology and Clinical Neuroscience Laboratory (LANNEC), Physiopathology Department - Institute of Biomedical Sciences (ICBM), Neurocience and East Neuroscience Departments, Faculty of Medicine, University of Chile, Santiago de Chile, Chile
- Geroscience Center for Brain Health and Metabolism, (GERO), Santiago de Chile, Chile
- Memory and Neuropsychiatric Center (CMYN), Memory Unit - Neurology Department, Hospital del Salvador and Faculty of Medicine, University of Chile, Santiago de Chile, Chile
- Servicio de Neurología, Departamento de Medicina, Clínica Alemana-Universidad del Desarrollo, Santiago de Chile, Chile
| | - Maria Isabel Behrens
- Centro de Investigación Clínica Avanzada (CICA), Facultad de Medicina-Hospital Clínico, Universidad de Chile, Independencia, Santiago, 8380453, Chile
- Departamento de Neurología y Neurocirugía, Hospital Clínico Universidad de Chile, Independencia, Santiago, 8380430, Chile
- Departamento de Neurociencia, Facultad de Medicina, Universidad de Chile, Independencia, Santiago, 8380453, Chile
- Departamento de Neurología y Psiquiatría, Clínica Alemana-Universidad del Desarrollo, Santiago, 8370065, Chile
| | - David Aguillon
- Grupo de Neurociencias de Antioquia de la Universidad de Antioquia, Medellín, Colombia
| | - Francisco Lopera
- Grupo de Neurociencias de Antioquia de la Universidad de Antioquia, Medellín, Colombia
| | - Mario A Parra
- School of Psychological Sciences and Health, University of Strathclyde, Glasgow, United Kingdom
| | - Diana Matallana
- PhD Neuroscience Program, Physiology and Psychiatry Departments, Pontificia Universidad Javeriana, Bogotá, Colombia
- Memory and Cognition Center Intellectus, Hospital Universitario San Ignacio, Bogotá, Colombia
- Mental Health Department, Hospital Universitario Fundación Santa Fe de Bogotá, Memory Clinic, Bogotá, Colombia
| | - Marcelo Adrián Maito
- Latin American Brain Health Institute (BrainLat), Universidad Adolfo Ibáñez, Santiago, Chile
- Cognitive Neuroscience Center (CNC), Universidad de San Andrés & CONICET, Buenos Aires, Argentina
| | - Adolfo M Garcia
- Global Brain Health Institute, University of California San Francisco, San Francisco, USA
- Cognitive Neuroscience Center (CNC), Universidad de San Andrés & CONICET, Buenos Aires, Argentina
- Departamento de Lingüística y Literatura, Facultad de Humanidades, Universidad de Santiago de Chile, Santiago, Chile
| | - Nilton Custodio
- Unit Cognitive Impairment and Dementia Prevention, Peruvian Institute of Neurosciences, Lima, Peru
| | - Alberto Ávila Funes
- Geriatrics Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
| | - Stefanie Piña-Escudero
- Global Brain Health Institute, University of California San Francisco, San Francisco, USA
- Memory and Aging Clinic, University of California San Francisco, San Francisco, USA
| | - Agustina Birba
- Latin American Brain Health Institute (BrainLat), Universidad Adolfo Ibáñez, Santiago, Chile
- Cognitive Neuroscience Center (CNC), Universidad de San Andrés & CONICET, Buenos Aires, Argentina
- Instituto Universitario de Neurociencia, Universidad de La Laguna, Tenerife, Spain
- Facultad de Psicología, Universidad de La Laguna, Tenerife, Spain
| | - Sol Fittipaldi
- Latin American Brain Health Institute (BrainLat), Universidad Adolfo Ibáñez, Santiago, Chile
- Global Brain Health Institute, Trinity College Dublin, Dublin, Ireland
- Cognitive Neuroscience Center (CNC), Universidad de San Andrés & CONICET, Buenos Aires, Argentina
| | - Agustina Legaz
- Latin American Brain Health Institute (BrainLat), Universidad Adolfo Ibáñez, Santiago, Chile
- Cognitive Neuroscience Center (CNC), Universidad de San Andrés & CONICET, Buenos Aires, Argentina
| | - Agustín Ibañez
- Latin American Brain Health Institute (BrainLat), Universidad Adolfo Ibáñez, Santiago, Chile.
- Global Brain Health Institute, University of California San Francisco, San Francisco, USA.
- Global Brain Health Institute, Trinity College Dublin, Dublin, Ireland.
- Cognitive Neuroscience Center (CNC), Universidad de San Andrés & CONICET, Buenos Aires, Argentina.
| |
Collapse
|
3
|
Sguigna PV, Tardo LM, Blackburn KM, Horton LA, Conger DL, Hogan RN, McCreary MC, Greenberg BM. Application of the International Interocular Difference Thresholds into Practice: Localising the Patient Experience. Neuroophthalmology 2022; 46:375-382. [PMID: 36544583 PMCID: PMC9762821 DOI: 10.1080/01658107.2022.2109687] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2021] [Revised: 06/30/2022] [Accepted: 07/28/2022] [Indexed: 12/24/2022] Open
Abstract
Demyelinating diseases of the central nervous system (CNS) often have neuro-ophthalmological manifestations, and retinal examination can be helpful in making the diagnosis. The latest iteration of optical coherence tomography (OCT)-based criteria for optic neuritis in multiple sclerosis has been developed in the research realm, but its application to clinical practice, and to the more uncommon demyelinating diseases requires further study. The ability to use OCT data to distinguish between various CNS demyelinating disorders could provide additional paraclinical tools to accurately diagnose patients. Furthermore, neuro-ophthalmological testing can define the extent of inflammatory damage in the CNS, independent of patient-reported history. New referrals for OCT at a tertiary multiple sclerosis and neuro-immunology referral centre (n = 167) were analysed retrospectively for the self-reporting of optic neuritis, serological test results, and diagnosis. Only approximately 30% of patients with a clinical history of unilateral optic neuritis solely had a unilateral optic neuropathy, nearly 40% of those subjects actually having evidence of bilateral optic neuropathies. Roughly 30% of patients reporting a history of bilateral optic neuritis did not have any evidence of structural disease, with 20% of these patients having a separate, intervenable diagnosis noted on macular scans. OCT is a useful adjunct diagnostic tool in the evaluation of demyelinating disease and has the ability to aid in a more accurate diagnosis for patients. Application of the international interocular difference thresholds to a clinical patient population generally reproduces the original results, emphasising their appropriateness. The analysis distinguishing the demyelinating diseases needs to be replicated in a blinded, multi-centre setting.
Collapse
Affiliation(s)
- Peter V. Sguigna
- Multiple Sclerosis & Neuroimmunology Division, Department of Neurology, University of Texas Southwestern, Dallas, Texas, USA
| | - Lauren M. Tardo
- Multiple Sclerosis & Neuroimmunology Division, Department of Neurology, University of Texas Southwestern, Dallas, Texas, USA
| | - Kyle M. Blackburn
- Multiple Sclerosis & Neuroimmunology Division, Department of Neurology, University of Texas Southwestern, Dallas, Texas, USA
| | - Lindsay A. Horton
- Multiple Sclerosis & Neuroimmunology Division, Department of Neurology, University of Texas Southwestern, Dallas, Texas, USA
| | - Darrel L. Conger
- Multiple Sclerosis & Neuroimmunology Division, Department of Neurology, University of Texas Southwestern, Dallas, Texas, USA
| | - R. Nick Hogan
- Multiple Sclerosis & Neuroimmunology Division, Department of Neurology, University of Texas Southwestern, Dallas, Texas, USA
- Department of Ophthalmology, University of Texas Southwestern, Dallas, Texas, USA
- Department of Pathology, University of Texas Southwestern, Dallas, Texas, USA
- Department of Neurosurgery, University of Texas Southwestern, Dallas, Texas, USA
| | - Morgan C. McCreary
- Multiple Sclerosis & Neuroimmunology Division, Department of Neurology, University of Texas Southwestern, Dallas, Texas, USA
| | - Benjamin M. Greenberg
- Multiple Sclerosis & Neuroimmunology Division, Department of Neurology, University of Texas Southwestern, Dallas, Texas, USA
| |
Collapse
|
6
|
Hancock LM, Hermann B, Schoonheim MM, Hetzel SJ, Brochet B, DeLuca J. Comparing diagnostic criteria for the diagnosis of neurocognitive disorders in multiple sclerosis. Mult Scler Relat Disord 2022; 58:103479. [PMID: 35033839 DOI: 10.1016/j.msard.2021.103479] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2021] [Accepted: 12/31/2021] [Indexed: 11/29/2022]
Abstract
BACKGROUND People with multiple sclerosis (MS) commonly experience cognitive impairment associated with the disease, but there is currently no agreed-upon operational definition for identifying the presence of that impairment, in either research or clinic contexts. The International MS Cognition Society (IMSCOGS) established a task force to begin to examine this issue and this paper represents the results of an initial pilot investigation. The aim of this paper was to compare two criterion sets to determine how to identify cognitive impairment among people with MS: the general Diagnostic and Statistical Manual (DSM-5) Criteria for neurocognitive disorders and criteria derived from existing MS research (scores in two domains fall 1.5 standard deviations below normative controls). METHODS Two hundred and ten people with MS presented for a brief cognitive evaluation in an MS Multidisciplinary Clinic at a midwestern academic medical center in the United States. Participants were generally middle aged (average 51.5 years), female (73.8%), and white (93.3%). McNemar's test was computed to compare the number of individuals whose cognitive test score performance was deemed cognitively normal, mildly impaired, or more significantly impaired. RESULTS DSM-5 criteria classified 87.2% of the sample as cognitively impaired, where 66.7% were more mildly impaired and 20.5% more significantly impaired. By contrast, research-based criteria classified 63.3% of the sample as cognitively impaired, with 49.5% as mildly impaired and 13.8% as more significantly impaired. CONCLUSIONS These findings indicate that compared to research criteria, the DSM-5 criteria classified far more people with MS as having cognitive impairment secondary to the disease. The paper discusses the potential benefits and drawbacks of the two diagnostic methods, highlighting that more work will be needed in order to establish a standardized and validated method for characterizing these impairments.
Collapse
Affiliation(s)
- Laura M Hancock
- University of Wisconsin School of Medicine and Public Health, Department of Neurology, 1685 Highland Avenue, MCFB Suite 7, Madison, Wisconsin 53705, USA; William S. Middleton VA Medical Center; 2500 Overlook Terrace, Madison, Wisconsin 53705, USA.
| | - Bruce Hermann
- University of Wisconsin School of Medicine and Public Health, Department of Neurology, 1685 Highland Avenue, MCFB Suite 7, Madison, Wisconsin 53705, USA.
| | - Menno M Schoonheim
- Department of Anatomy and Neurosciences, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, PO Box 7057, 1007MB, Amsterdam, The Netherlands.
| | - Scott J Hetzel
- University of Wisconsin School of Medicine and Public Health, Department of Biostatistics and Medical Informatics, WARF Room 201, 610 Walnut Street, Madison, Wisconsin 53726, USA.
| | - Bruno Brochet
- Neurocentre Magendie, INSERM U 1215, Université de Bordeaux, 146, rue Léo Saignat, 33077 Bordeaux cedex, France.
| | - John DeLuca
- Kessler Foundation, 1199 Pleasant Valley Way, West Orange, New Jersey 07052, USA; Rutgers, New Jersey Medical School, Department of Physical Medicine and Rehabilitation, 185 S Orange Ave, Newark, New Jersey 07103, USA.
| |
Collapse
|